Skip to main content

Rigel Pharmaceuticals (RIGL) Reports Q4 Earnings: It’s A Beat

Rigel Pharmaceuticals, Inc. (RIGL) is flat to $3.11 in pre-market trading after it reported fiscal results for the fourth quarter. In its quarterly report, the drug developer said it earned ($0.25) per share, above the ($0.27) per share analysts were expecting. Revenue rose 43.5% to $8.25 million, well above views for $2.5 million. On valuation […] View the full post at: Rigel Pharmaceuticals (RIGL) Reports Q4 Earnings: It’s A Beat Related posts: Fidelity Discloses 14.97% stake in Ariad Encouraging Reports but Meaningful Growth is Still a Ways Off After-Hours Earnings (March 9)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.